Several analysts have recently updated their ratings and price targets for Fortress Biotech (NASDAQ: FBIO):

  • 7/11/2017 – Fortress Biotech is now covered by analysts at Rodman & Renshaw. They set a “buy” rating and a $11.00 price target on the stock.
  • 7/11/2017 – Fortress Biotech was given a new $11.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 7/11/2017 – Fortress Biotech was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. “
  • 7/4/2017 – Fortress Biotech had its “buy” rating reaffirmed by analysts at FBR & Co.
  • 6/13/2017 – Fortress Biotech was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.00 price target on the stock. According to Zacks, “Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. “
  • 6/7/2017 – Fortress Biotech was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) opened at 4.55 on Monday. The stock’s market capitalization is $229.01 million. The company’s 50 day moving average price is $4.27 and its 200 day moving average price is $3.33. Fortress Biotech, Inc. has a one year low of $1.88 and a one year high of $5.05.

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The business had revenue of $2.78 million during the quarter, compared to analysts’ expectations of $47.04 million. Fortress Biotech had a negative net margin of 269.14% and a negative return on equity of 63.99%. On average, analysts expect that Fortress Biotech, Inc. will post ($1.28) earnings per share for the current fiscal year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Receive News & Ratings for Fortress Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.